Sign In
Buy AFMD
$0.182
+0 (+0%)
At Close: Sep 16, 2025
Centene (CNC) Q2 Earnings Beat Estimates, Boosts 2022 View
05:20pm, Tuesday, 26'th Jul 2022 Zacks Investment Research
Centene (CNC) currently has $3.4 billion remaining in its share buyback program.
6 Blue-Chip Stocks to Sell Now
11:44am, Monday, 18'th Jul 2022
This article is about 6 blue-chip stocks to sell now. The stocks are overvalued or could fall due to the recession or from a downgrade in analysts' forecasts of their earnings.
Can Elevance Health (ELV) Beat Q2 Earnings on Membership Growth?
04:43pm, Friday, 15'th Jul 2022 Zacks Investment Research
Elevance Health's (ELV) second-quarter results are likely to reflect improved Commercial Business operations, driven by the robust growth in risk-based areas.
UnitedHealth (UNH) to Post Q2 Earnings: What to Expect?
12:19pm, Tuesday, 12'th Jul 2022 Zacks Investment Research
UnitedHealth Group's (UNH) second-quarter results are likely to reflect improving premiums, products and higher expenses.
Affimed Establishes Scientific Advisory Board
08:00pm, Thursday, 30'th Jun 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, June 30, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back t
Affimed: Preparing For Key Inflection Points
11:02am, Wednesday, 29'th Jun 2022
Affimed has generated an impressive pipeline of innate cell engagers programs created using their three-pronged development strategy. These programs target high unmet needs and large market opportunit
Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
02:31pm, Friday, 10'th Jun 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, June 10, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back th
Affimed N.V. (AFMD) CEO Adi Hoess on Q1 2022 Results - Earnings Call Transcript
12:24pm, Wednesday, 01'st Jun 2022
Affimed N.V. (NASDAQ:AFMD ) Q1 2022 Results Conference Call June 1, 2022 8:30 AM ET Company Participants Alex Fudukidis - Head of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstri
Affimed N.V. (AFMD) Reports Q1 Loss, Misses Revenue Estimates
11:55am, Wednesday, 01'st Jun 2022 Zacks Investment Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 11.11% and 9.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress
10:30am, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, June 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back th
Affimed N.V. (AFMD) Reports Q1 Loss, Misses Revenue Estimates
09:02am, Wednesday, 01'st Jun 2022
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 11.11% and 9.57%, respectively, for the quarter ended March 2022.
Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
09:05pm, Thursday, 26'th May 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, May 26, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back t
Affimed to Present at the 2022 Jefferies Healthcare Conference
10:30am, Thursday, 26'th May 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, May 26, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back th
Affimed to Present at the 2022 Jefferies Healthcare Conference
06:30am, Thursday, 26'th May 2022
HEIDELBERG, Germany, May 26, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back thei
Affimed N.V. (AFMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
07:00pm, Wednesday, 25'th May 2022 Zacks Investment Research
Affimed N.V. (AFMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
